|
| |
nAcRalpha-18C
| Symbol: | nAcRalpha-18C | | Name(s): | CG32538 gene product from transcript CG32538-RB | | Type: | protein-coding | | Organism: | Drosophila melanogaster | | Synonyms: | - | | Links: |
Pubmed,
Entrez Gene,
Map Viewer.
|
Gene Information from Publications |
| Publication Link |
Summary of findings |
| 16494528 |
essential role for the Dalpha7 nicotinic acetylcholine receptor in giant fiber-mediated escape in Drosophila |
| 15228604 |
In addition to the formation of homomeric nAChR complexes, evidence has been obtained from both radioligand binding and co-immunoprecipitation studies for the co-assembly of Dalpha6 and Dalpha7 into heteromeric cell surface complexes |
Press Releases on nAcRalpha-18C:
|
 |
| New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease |
11th June, 2009 |
|
COLLEGEVILLE, Pennsylvania, June 11 /PRNewswire/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's
(NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13*
|
| FDA Grants Priority Review Status to Prevnar 13 Marketing Application |
7th May, 2009 |
|
COLLEGEVILLE, Pennsylvania, May 7 /PRNewswire/ -- -- Candidate vaccine designed to protect against the 13 most prevalent
serotypes associated with pneumococcal disease --
Wyeth
|
| Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers |
31st March, 2009 |
|
COLLEGEVILLE, Pennsylvania, March 31 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today
that it has submitted a Biologic License Application (BLA) to the U.S.
|
| Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children |
3rd December, 2008 |
Wyeth Pharmaceuticals, Wyeth |
COLLEGEVILLE, Pa., Dec. 3 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals,
a division of Wyeth (NYSE: WYE), announced today that it has submitted a
marketing authorization application (MAA) to
|
| Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two |
27th October, 2008 |
Wyeth Pharmaceuticals |
- Data presented at the joint annual meeting of ICAAC and IDSA
- Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and
|
nAcRalpha-18C results (if any) from reagent suppliers | 
|
Search Bioportfolio and other Life Science Sites for nAcRalpha-18C,
or search for nAcRalpha-18C on BioPortfolio's antibody search engine.
This page has been viewed 66 times
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
